These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38433043)

  • 21. Chemotherapy treatments, costs of care, and survival for patients diagnosed with small cell lung cancer: A SEER-Medicare study.
    Shao C; He J; Kachroo S; Jin F
    Cancer Med; 2019 Dec; 8(18):7613-7622. PubMed ID: 31668011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study.
    López A; Gutiérrez A; Palacios A; Blancas I; Navarrete M; Morey M; Perelló A; Alarcón J; Martínez J; Rodríguez J
    Eur J Haematol; 2008 Feb; 80(2):127-32. PubMed ID: 18005385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims.
    Freedland SJ; Davis MR; Epstein AJ; Arondekar B; Ivanova JI
    Adv Ther; 2023 Oct; 40(10):4480-4492. PubMed ID: 37531024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States.
    Keating SJ; Gu T; Jun MP; McBride A
    Transplant Cell Ther; 2022 Jul; 28(7):404.e1-404.e6. PubMed ID: 35354101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. (R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study.
    Collignon A; Houillier C; Ahle G; Chinot O; Choquet S; Schmitt A; Agape P; Soussain C; Hoang-Xuan K; Tabouret E
    Ann Hematol; 2019 Apr; 98(4):915-922. PubMed ID: 30535802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.
    El Gnaoui T; Dupuis J; Belhadj K; Jais JP; Rahmouni A; Copie-Bergman C; Gaillard I; Diviné M; Tabah-Fisch I; Reyes F; Haioun C
    Ann Oncol; 2007 Aug; 18(8):1363-8. PubMed ID: 17496309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment patterns and costs among US patients with diffuse large B-cell lymphoma not treated with 2L stem cell transplantation.
    Acheampong T; Gu T; Le TK; Keating SJ
    Future Oncol; 2024 Mar; 20(10):623-634. PubMed ID: 38230990
    [No Abstract]   [Full Text] [Related]  

  • 28. Microcosting Analysis of Diffuse Large B-Cell Lymphoma Treatment in Malawi.
    Painschab MS; Kohler RE; Kasonkanji E; Zuze T; Kaimila B; Nyasosela R; Nyirenda R; Krysiak R; Gopal S
    J Glob Oncol; 2019 Jul; 5():1-10. PubMed ID: 31322992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma.
    Griffiths RI; Gleeson ML; Mikhael J; Dreyling MH; Danese MD
    Cancer; 2012 Dec; 118(24):6079-88. PubMed ID: 22648454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
    Ferrara F; Ravasio R
    Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.
    Nowakowski GS; Yoon DH; Peters A; Mondello P; Joffe E; Fleury I; Greil R; Ku M; Marks R; Kim K; Zinzani PL; Trotman J; Huang D; Waltl EE; Winderlich M; Kurukulasuriya NC; Ambarkhane S; Hess G; Salles G
    Clin Cancer Res; 2022 Sep; 28(18):4003-4017. PubMed ID: 35674661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study.
    Ghosh N; Emond B; Lafeuille MH; Côté-Sergent A; Lefebvre P; Huang Q
    Clin Ther; 2021 Aug; 43(8):1285-1299. PubMed ID: 34332789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic burden in treated Japanese patients with relapsed/refractory large B-cell lymphoma.
    Tsutsué S; Makita S; Yi J; Crawford B
    Future Oncol; 2021 Nov; 17(33):4511-4525. PubMed ID: 34414783
    [No Abstract]   [Full Text] [Related]  

  • 34. Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs.
    Squires P; Puckett J; Ryland KE; Kamal-Bahl S; Raut M; Doshi JA; Huntington SF
    Leuk Lymphoma; 2023; 64(11):1752-1770. PubMed ID: 37497877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma.
    Cox MC; Pelliccia S; Marcheselli L; Battistini R; Arcari A; Borza PA; Patti C; Casaroli I; di Landro F; Di Napoli A; Fabbri F; Caridi M; Tafuri A; Bocci G; Musuraca G
    Invest New Drugs; 2019 Jun; 37(3):548-558. PubMed ID: 31028663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors affecting survival in elderly patients with diffuse large B-Cell lymphoma.
    Ulu BU; Yiğenoğlu TN; Başcı S; Bakırtaş M; Şahin D; Darçın T; Yaman S; Bozan E; Seçilmiş S; Candır BA; Yıldız J; İskender D; Baysal NA; Çakar MK; Dal MS; Altuntaş F
    Leuk Res; 2021 Nov; 110():106700. PubMed ID: 34481125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
    Knight C; Hind D; Brewer N; Abbott V
    Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients.
    Çağlayan Ç; Goldstein JS; Ayer T; Rai A; Flowers CR
    Cancer; 2019 Jun; 125(11):1837-1847. PubMed ID: 30707765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients With Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of SEER-Medicare Data.
    Swami U; Aggarwal H; Zhou M; Jiang S; Kim J; Li W; Laliberté F; Emond B; Agarwal N
    Clin Genitourin Cancer; 2023 Oct; 21(5):517-529. PubMed ID: 37248148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
    Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
    Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.